Sintilimab after surgery for node-positive esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove esophageal cancer within the past 4 to 12 weeks.
- Your cancer had spread to lymph nodes (node-positive) but not to distant organs.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have adequate blood cell counts and liver/kidney function.
- You do not have active autoimmune disease, hepatitis B or C, or HIV.
- You have not had other cancer treatments after surgery (like chemo or radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.